Suppression of histamine and allergen induced itch and swelling with topical minocycline cream

Background:

Allergic skin reactions, characterized by itching and swelling, affect many individuals and are commonly managed with steroid-based therapies that can cause side effects with prolonged use. There is a need for safer, effective alternatives. Research at SUNY Downstate explored minocycline, known for its anti-inflammatory properties, as a potential treatment to reduce allergic skin responses, leading to the development of this novel topical cream. The research included clinical evaluation involving adults with allergic rhinitis or asthma to assess efficacy against histamine- and allergen-induced symptoms.

Technology Overview:

This innovative technology is a topical cream formulation containing 2% minocycline, an antibiotic with anti-inflammatory effects. The cream works by inhibiting the skin’s inflammatory response triggered by histamine and allergens, which are primary mediators of itch and swelling in allergic reactions. Clinical studies involving eight adult subjects demonstrated that the application of this cream resulted in a significant reduction in both histamine-induced swelling and itch intensity compared to a placebo. Additionally, the cream effectively decreased allergen-induced skin induration, highlighting its potential to manage various allergic responses without relying on steroids. The key novelty lies in repurposing minocycline—traditionally used for infections—as a topical agent to modulate allergic inflammatory pathways safely and effectively. This innovation addresses a critical gap by providing a non-steroidal treatment option, which reduces concerns related to steroid-associated side effects. Its demonstrated efficacy in controlled studies and presentation at major allergy conferences underline its potential clinical and commercial value.

Advantages:

•    Non-steroidal treatment option that avoids common side effects of corticosteroids.
•    Significantly reduces histamine- and allergen-induced itching and swelling.
•    Utilizes minocycline’s anti-inflammatory properties in a novel topical formulation.
•    Demonstrated efficacy in clinical studies involving allergic rhinitis and asthma patients.
•    Potentially safer for long-term use in managing allergic skin conditions.

Applications:

•    Treatment of allergic skin reactions including itching and swelling caused by histamine release.
•    Management of symptoms associated with allergic rhinitis and asthma-related skin manifestations.
•    Use as a non-steroidal alternative in dermatology for allergic dermatitis and other inflammatory skin conditions.
•    Potential incorporation into allergy management protocols to improve patient comfort and reduce reliance on steroids.

Intellectual Property Summary:

Know-how based

Stage of Development:

TRL 3 – Experimental Proof of Concept

Licensing Status:

This technology is available for licensing.